CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer.
CTX-2026 (1 μg/mL; 12 h) redirects the cytotoxic activity of Vγ9Vδ2 T cells from multiple donors against BTN3A1+OVCAR3 cells or primary HGSOC cells[1].CTX-2026 (1 μg/mL; 6 d) shows a rescuing effect on nonablated CD45+ T cells[1].
CTX-2026 (5 mg/kg; i.p. for 15 days every 3 days once) effects the tumor growth of NY-OVCAR3 tumor mice[1].
References:
[1]. Payne KK, et al. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020 Aug 21;369(6506):942-949.